Medical Information

The duration of Upadacitinib medication needs to be comprehensively judged based on the type of indication, treatment response, and individual situation. The key efficacy evaluation period is usually 3-6 months, and the specific number of months of medication needs to be dynamically adjusted by a specialist doctor according to clinical indicators.

Duration of medication for different indications

(1) Rheumatoid arthritis: It is recommended to continue medication for at least 9-12 months. After standard treatment, it can be converted to long-term maintenance. Most patients need to use it continuously to control the progression of the disease.

(2) Atopic dermatitis: Moderate to severe patients usually take 6-12 months, and about 75% of patients achieve significant therapeutic effects after 16 weeks of medication. Gradual reduction may be considered, but treatment needs to be maintained.

2. Factors for adjusting medication duration

(1) Efficacy evaluation: Monthly monitoring of joint swelling or skin lesion area. Those who fail to meet the standard need to extend the medication cycle, and some patients need to continue for more than 24 months.

(2) Safety considerations: In the event of adverse reactions such as deep vein thrombosis, medication may be suspended for 1-2 months before evaluating whether to continue treatment.

3 Differences in medication use among special populations

(1) Elderly patients: It is recommended to reassess the necessity of medication every 6 months, as the actual number of months of medication may be extended by 30% -50% compared to younger patients.

(2) Co infected individuals: It is necessary to control the infection before continuing medication, and the overall treatment period may be extended by 2-3 months.